Letybo (Botulinum Toxin Type A)

Botulinum toxin type A blocks the release of acetylcholine at the neuromuscular junction by cleaving SNAP‑25 proteins, preventing nerve‑muscle signal transmission. This results in temporary paralysis of the injected muscle or gland, reducing abnormal contractions or secretions for several weeks.

The dose of Letybo is individualized by the prescribing clinician based on the specific indication, muscle size, and patient response. Dosing units are expressed in international units (U) and administered by intramuscular injection under aseptic conditions.

Safety data for botulinum toxin type A in pregnancy and lactation are limited. It should be used only if the potential therapeutic benefit outweighs any possible risk to the fetus or infant, and clinicians should discuss uncertainties with the patient.

To place an order, submit an enquiry on the Letybo product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Letybo contains the same purified botulinum toxin type A protein as other branded preparations, offering comparable efficacy and safety when administered by trained professionals. Differences may lie in formulation excipients, vial size, and regulatory approvals, which can affect handling, storage and pricing.

Letybo must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Prior to use, the vial should be allowed to reach room temperature and inspected for particulate matter; reconstitution is performed with sterile diluent according to the label instructions.

Letybo is supplied as a sterile powder for reconstitution and is given by intramuscular injection into the targeted muscle or gland. The injection is performed by a qualified healthcare professional using aseptic technique, with dosage and injection sites determined by the clinical indication.

The most serious risks include systemic spread of toxin leading to botulism‑like symptoms such as dysphagia, respiratory compromise, or generalized muscle weakness, as well as severe allergic reactions. Prompt medical attention is required if these symptoms develop after treatment.

Letybo is contraindicated in individuals with a known hypersensitivity to botulinum toxin type A or any of its excipients, and should be used with caution or avoided in patients with active infection at the injection site, neuromuscular disorders like myasthenia gravis, or those taking interacting medications such as aminoglycosides.